Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | POLR1A | O95602 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629270 | 0.80 | SCN5A (0.61) | HTTPPARGHPGDKDM4EALDH1A1 | |
| SCHEMBL4371080 | 0.80 | RAD52 (0.67) | HTTKCNH2PLK1RAD52MMP3 | |
| SCHEMBL4628722 | 0.78 | SCN5A (0.55) | PLK1MMP3HDAC8HPGDKDM4E | |
| SCHEMBL5427460 | 0.78 | MMP3 (0.67) | PLK1MMP3HDAC8HPGDKDM4E | |
| SCHEMBL4629465 | 0.76 | HDAC8 (0.57) | PLK1MMP3HDAC8HPGDKDM4E | |
| SCHEMBL4629230 | 0.76 | SCN5A (0.68) | PLK1RAD52MMP3HDAC8MEN1 | |
| SCHEMBL9331839 | 0.75 | HTT (0.59) | HTTKCNH2RAD52HPGDKDM4E | |
| SCHEMBL6331260 | 0.74 | PLK1 (0.57) | PLK1MMP3HDAC8HPGDKDM4E | |
| SCHEMBL4629442 | 0.74 | LMNA (0.54) | PLK1MMP3HDAC8HPGDKDM4E | |
| SCHEMBL3643350 | 0.74 | HPGD (0.62) | HTTPLK1MMP3HDAC8PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | claimed |
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | HTT 20/4885KCNH2 1361/4885PLK1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.